pp-043 Solution for infusion

Indication: Advanced or metastatic solid tumours (e.g., non-small cell lung cancer, head & neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, malignant melanoma). Clinical stage / status: Phase 1 ( trial in the USA). Mechanism / differentiating features: Human monoclonal antibody targeting LILRB1 (Leukocyte Immunoglobulin-Like Receptor B1) — blocks the binding of tumour-expressed HLA-G to LILRB1 on immune cells, thereby activating multiple immune cell types (T cells, NK cells, macrophages) simultaneously. Route / form: Intravenous infusion of the monoclonal antibody. Differentiation / unmet need: unique mechanism engaging multiple immune cell types rather than just T-cells; addresses solid tumor patients who have progressed on standard treatments.